Comparison of post-rmission stratgis in acut myloid lukmia: Autologous hmatopoitic stm cll transplantation vrsus consolidation chmothrapy
Hematology Reports, vol.12, no.3, pp.51-54, 2020 (ESCI, Scopus)
- Publication Type: Article / Article
- Volume: 12 Issue: 3
- Publication Date: 2020
- Doi Number: 10.4081/hr.2020.8380
- Journal Name: Hematology Reports
- Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, EMBASE, Directory of Open Access Journals
- Page Numbers: pp.51-54
- Keywords: Acute myeloid leukemia, Autolo-gous hematopoietic stem cell transplantation, Consolidation chemotherapy, Leukemia relapse, Prognosis
- Open Archive Collection: AVESIS Open Access Collection
- Ankara Yıldırım Beyazıt University Affiliated: No
Abstract
Autologous Hematopoietic Stem Cell Transplantation (auto-HSCT) has become a therapeutic option for first-line consolidation in Acute Myeloid Leukemia (AML) patients with favorable and intermediate risk features. A total of 101 AML patients in first complete remission, who were not eligible for allogeneic HSCT, were randomized to receive intensive cytarabine-based chemotherapy or to undergo auto-HSCT. The probability of LFS was significantly better in auto-HSCT recipients compared to chemotherapy arm (43% vs 4.8%, p=0.008). At the end of 915 (30-4470) days of follow-up, the probability of overall survival was better in auto-HSCT group compared to chemotherapy, without statistical significance (79.2% vs 38.8%, p=0.054). Multivariate analysis revealed a significant predictive impact of cytogenetic risk status on OS (p=0.002, HR: 2.824, 95% CI: 1.445-5.521). Auto-HSCT is considered as an effective consolidation approach in favorable and intermadiate risk AML patients.